Pharma Equity Group A/S (PEG.CO)
DKK 0.18
(-2.17%)
DKK 0.18
(-2.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.33 Million DKK | 14.44% |
| 2022 | 71.07 Million DKK | 11.67% |
| 2021 | 63.64 Million DKK | 10.53% |
| 2020 | 57.58 Million DKK | -28.77% |
| 2019 | 80.83 Million DKK | 0.0% |
| 2018 | 80.83 Million DKK | -6.33% |
| 2017 | 86.3 Million DKK | -31.37% |
| 2016 | 125.75 Million DKK | -0.4% |
| 2015 | 126.25 Million DKK | 1.84% |
| 2014 | 123.97 Million DKK | -50.66% |
| 2013 | 251.23 Million DKK | -50.14% |
| 2012 | 503.84 Million DKK | -0.77% |
| 2011 | 507.76 Million DKK | 2.11% |
| 2010 | 497.26 Million DKK | 556.84% |
| 2009 | 75.7 Million DKK | -71.07% |
| 2008 | 261.67 Million DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 76.63 Million DKK | -2.1% |
| 2024 Q1 | 78.28 Million DKK | -3.75% |
| 2023 Q2 | 85.62 Million DKK | -7.12% |
| 2023 Q1 | 92.18 Million DKK | 29.71% |
| 2023 Q3 | 83.4 Million DKK | -2.59% |
| 2023 FY | 81.33 Million DKK | 14.44% |
| 2023 Q4 | 81.33 Million DKK | -2.49% |
| 2022 Q2 | 67.43 Million DKK | 0.0% |
| 2022 FY | 71.07 Million DKK | 11.67% |
| 2022 Q4 | 71.07 Million DKK | 0.0% |
| 2021 FY | 63.64 Million DKK | 10.53% |
| 2021 Q4 | 63.64 Million DKK | 0.0% |
| 2021 Q2 | 58.12 Million DKK | 0.0% |
| 2020 Q4 | 57.58 Million DKK | 0.0% |
| 2020 FY | 57.58 Million DKK | -28.77% |
| 2020 Q2 | 72.37 Million DKK | 0.0% |
| 2019 Q4 | 80.83 Million DKK | 0.0% |
| 2019 Q2 | 77.08 Million DKK | 0.0% |
| 2019 FY | 80.83 Million DKK | 0.0% |
| 2018 Q4 | 80.83 Million DKK | 0.0% |
| 2018 FY | 80.83 Million DKK | -6.33% |
| 2018 Q2 | 126.58 Million DKK | 0.0% |
| 2017 Q2 | 126.31 Million DKK | 0.0% |
| 2017 FY | 86.3 Million DKK | -31.37% |
| 2017 Q4 | 86.3 Million DKK | 0.0% |
| 2016 Q2 | 125.74 Million DKK | -0.12% |
| 2016 FY | 125.75 Million DKK | -0.4% |
| 2016 Q1 | 125.88 Million DKK | -0.29% |
| 2015 Q2 | 124.01 Million DKK | 0.22% |
| 2015 Q4 | 126.25 Million DKK | -0.24% |
| 2015 Q1 | 123.74 Million DKK | -0.18% |
| 2015 FY | 126.25 Million DKK | 1.84% |
| 2015 Q3 | 126.55 Million DKK | 2.05% |
| 2014 Q4 | 123.97 Million DKK | 242980.39% |
| 2014 Q3 | 51 Thousand DKK | -70.86% |
| 2014 FY | 123.97 Million DKK | -50.66% |
| 2014 Q1 | 213.78 Million DKK | -14.91% |
| 2014 Q2 | 175 Thousand DKK | -99.92% |
| 2013 Q2 | 395.4 Million DKK | -20.86% |
| 2013 FY | 251.23 Million DKK | -50.14% |
| 2013 Q3 | 327.72 Million DKK | -17.11% |
| 2013 Q4 | 251.23 Million DKK | -23.34% |
| 2013 Q1 | 499.61 Million DKK | -0.84% |
| 2012 Q3 | 519.46 Million DKK | 1.07% |
| 2012 FY | 503.84 Million DKK | -0.77% |
| 2012 Q4 | 503.84 Million DKK | -3.01% |
| 2012 Q1 | 527.93 Million DKK | 3.97% |
| 2012 Q2 | 513.97 Million DKK | -2.64% |
| 2011 Q2 | 501.29 Million DKK | -0.12% |
| 2011 FY | 507.76 Million DKK | 2.11% |
| 2011 Q3 | 503.14 Million DKK | 0.37% |
| 2011 Q4 | 507.76 Million DKK | 0.92% |
| 2011 Q1 | 501.91 Million DKK | 0.94% |
| 2010 FY | 497.26 Million DKK | 556.84% |
| 2010 Q2 | 74.94 Million DKK | 0.0% |
| 2010 Q3 | 73.64 Million DKK | -1.73% |
| 2010 Q4 | 497.26 Million DKK | 575.22% |
| 2009 FY | 75.7 Million DKK | -71.07% |
| 2009 Q4 | 75.7 Million DKK | 0.0% |
| 2008 FY | 261.67 Million DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ALK-Abelló A/S | 6.72 Billion DKK | 98.791% |
| Bavarian Nordic A/S | 14.35 Billion DKK | 99.433% |
| Genmab A/S | 35.28 Billion DKK | 99.77% |
| Gubra A/S | 625.28 Million DKK | 86.992% |
| Novo Nordisk A/S | 314.48 Billion DKK | 99.974% |
| Orphazyme A/S | 19.31 Million DKK | -321.163% |
| Zealand Pharma A/S | 3.19 Billion DKK | 97.457% |